Is there a role for topically delivered eicosapentaenoic acid in the treatment of psoriasis?

Mohd Hanif Zulfakar, Michael Edwards, Charles Martin Heard

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The n-3 fatty acids have demonstrable biological activities and have been associated with many health improvements from child brain development to arthritis. In this review we sought to pull together the works that have examined the potential use of n-3 fatty acids in psoriasis. The rationale of using EPA and/or its metabolites is supported by findings which suggest that it has anti-inflammatory properties and plays an important role in the resolution phase of inflammation. EPA use in psoriasis has also been demonstrated in trials using oral, intravenous, and topical preparations, with generally positive outcomes. Depth profile analysis revealed that EPA and its metabolite, 15-HEPE are deposited in the epidermis, particularly in the metabolically active basal layer. This is considered advantageous in psoriasis therapy. Currently there are many unknowns about psoriasis aetiology and the effects of blocking different cytokines have on the disease progression. Furthermore not enough is known about EPA effects on cellular immunity other than via prostaglandin and leukotriene synthesis to fully understand the mode of action of EPA. However, evidence so far suggests EPA does have a potential role in the treatment of psoriasis, in particular for topical treatments either as an active anti-inflammatory agent by itself, or as a dual action permeation enhancer for other anti-psoriatic treatments. The challenges include optimising the delivery of EPA to the skin and determining the derivatives of EPA which would give maximal effects, and overcoming pharmacokinetic and formulation problems to optimally deliver EPA to its intended target cells.

Original languageEnglish
Pages (from-to)284-291
Number of pages8
JournalEuropean Journal of Dermatology
Volume17
Issue number4
DOIs
Publication statusPublished - Jul 2007
Externally publishedYes

Fingerprint

Eicosapentaenoic Acid
Psoriasis
Omega-3 Fatty Acids
Anti-Inflammatory Agents
Leukotrienes
Child Development
Epidermis
Cellular Immunity
Arthritis
Prostaglandins
Disease Progression
Research Design
Pharmacokinetics
Cytokines
Inflammation
Skin
Health
Brain

Keywords

  • Eicosapentaenoic acid
  • Fish oil
  • Inflammation
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology

Cite this

Is there a role for topically delivered eicosapentaenoic acid in the treatment of psoriasis? / Zulfakar, Mohd Hanif; Edwards, Michael; Heard, Charles Martin.

In: European Journal of Dermatology, Vol. 17, No. 4, 07.2007, p. 284-291.

Research output: Contribution to journalArticle

@article{eb86873fc35344b7a2fc2c0c2cedd42a,
title = "Is there a role for topically delivered eicosapentaenoic acid in the treatment of psoriasis?",
abstract = "The n-3 fatty acids have demonstrable biological activities and have been associated with many health improvements from child brain development to arthritis. In this review we sought to pull together the works that have examined the potential use of n-3 fatty acids in psoriasis. The rationale of using EPA and/or its metabolites is supported by findings which suggest that it has anti-inflammatory properties and plays an important role in the resolution phase of inflammation. EPA use in psoriasis has also been demonstrated in trials using oral, intravenous, and topical preparations, with generally positive outcomes. Depth profile analysis revealed that EPA and its metabolite, 15-HEPE are deposited in the epidermis, particularly in the metabolically active basal layer. This is considered advantageous in psoriasis therapy. Currently there are many unknowns about psoriasis aetiology and the effects of blocking different cytokines have on the disease progression. Furthermore not enough is known about EPA effects on cellular immunity other than via prostaglandin and leukotriene synthesis to fully understand the mode of action of EPA. However, evidence so far suggests EPA does have a potential role in the treatment of psoriasis, in particular for topical treatments either as an active anti-inflammatory agent by itself, or as a dual action permeation enhancer for other anti-psoriatic treatments. The challenges include optimising the delivery of EPA to the skin and determining the derivatives of EPA which would give maximal effects, and overcoming pharmacokinetic and formulation problems to optimally deliver EPA to its intended target cells.",
keywords = "Eicosapentaenoic acid, Fish oil, Inflammation, Psoriasis",
author = "Zulfakar, {Mohd Hanif} and Michael Edwards and Heard, {Charles Martin}",
year = "2007",
month = "7",
doi = "10.1684/ejd.2007.0201",
language = "English",
volume = "17",
pages = "284--291",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "John Libbey Eurotext",
number = "4",

}

TY - JOUR

T1 - Is there a role for topically delivered eicosapentaenoic acid in the treatment of psoriasis?

AU - Zulfakar, Mohd Hanif

AU - Edwards, Michael

AU - Heard, Charles Martin

PY - 2007/7

Y1 - 2007/7

N2 - The n-3 fatty acids have demonstrable biological activities and have been associated with many health improvements from child brain development to arthritis. In this review we sought to pull together the works that have examined the potential use of n-3 fatty acids in psoriasis. The rationale of using EPA and/or its metabolites is supported by findings which suggest that it has anti-inflammatory properties and plays an important role in the resolution phase of inflammation. EPA use in psoriasis has also been demonstrated in trials using oral, intravenous, and topical preparations, with generally positive outcomes. Depth profile analysis revealed that EPA and its metabolite, 15-HEPE are deposited in the epidermis, particularly in the metabolically active basal layer. This is considered advantageous in psoriasis therapy. Currently there are many unknowns about psoriasis aetiology and the effects of blocking different cytokines have on the disease progression. Furthermore not enough is known about EPA effects on cellular immunity other than via prostaglandin and leukotriene synthesis to fully understand the mode of action of EPA. However, evidence so far suggests EPA does have a potential role in the treatment of psoriasis, in particular for topical treatments either as an active anti-inflammatory agent by itself, or as a dual action permeation enhancer for other anti-psoriatic treatments. The challenges include optimising the delivery of EPA to the skin and determining the derivatives of EPA which would give maximal effects, and overcoming pharmacokinetic and formulation problems to optimally deliver EPA to its intended target cells.

AB - The n-3 fatty acids have demonstrable biological activities and have been associated with many health improvements from child brain development to arthritis. In this review we sought to pull together the works that have examined the potential use of n-3 fatty acids in psoriasis. The rationale of using EPA and/or its metabolites is supported by findings which suggest that it has anti-inflammatory properties and plays an important role in the resolution phase of inflammation. EPA use in psoriasis has also been demonstrated in trials using oral, intravenous, and topical preparations, with generally positive outcomes. Depth profile analysis revealed that EPA and its metabolite, 15-HEPE are deposited in the epidermis, particularly in the metabolically active basal layer. This is considered advantageous in psoriasis therapy. Currently there are many unknowns about psoriasis aetiology and the effects of blocking different cytokines have on the disease progression. Furthermore not enough is known about EPA effects on cellular immunity other than via prostaglandin and leukotriene synthesis to fully understand the mode of action of EPA. However, evidence so far suggests EPA does have a potential role in the treatment of psoriasis, in particular for topical treatments either as an active anti-inflammatory agent by itself, or as a dual action permeation enhancer for other anti-psoriatic treatments. The challenges include optimising the delivery of EPA to the skin and determining the derivatives of EPA which would give maximal effects, and overcoming pharmacokinetic and formulation problems to optimally deliver EPA to its intended target cells.

KW - Eicosapentaenoic acid

KW - Fish oil

KW - Inflammation

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=34447313149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447313149&partnerID=8YFLogxK

U2 - 10.1684/ejd.2007.0201

DO - 10.1684/ejd.2007.0201

M3 - Article

VL - 17

SP - 284

EP - 291

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 4

ER -